At Perspectum, we have developed a series of FDA-cleared products with dedicated CPT codes (for reimbursement in the USA).  Our technology supports clinicians in a range of aspects of the metabolic syndrome: NAFLD/NASH, T2D, liver cancer, pancreatitis, ….  Our systems comprise multimodal quantitative MRI, decision support for liver surgery, analysis of the biliary tree, and assessment of organ damage as a result of Covid.  This talk summarises the technology and the clinical evidence that underpins its use.